Alterations in the PI3K and CTNNB1 pathways among patients with ovarian endometrioid carcinomas were associated with prolonged survival, whereas patients with ovarian mucinous carcinomas harboring alterations in the PI3K pathway had reduced survival and may benefit from additional targeted therapeutic approaches. This evidence concerns the gene PIK3CA and ovarian mucinous adenocarcinoma.